西维来司他钠治疗急性肺挫伤患者的疗效及对炎性因子的影响研究  

Study on the efficacy of sivelestat sodium in the treatment of patients with acute pulmonary contusion and influence on inflammatory factors

作　　者：王利剑 强新华[2] WANG Li-jian;QIANG Xin-hua(Third People's Hospital of Shunde District,(Beijiao Hospital of Shunde District),Foshan 528311,China)

机构地区：[1]佛山市顺德区第三人民医院(佛山市顺德区北滘医院),528311 [2]佛山市第一人民医院重症医学科,528000

出　　处：《中国现代药物应用》2023年第14期7-10,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探究西维来司他钠治疗急性肺挫伤患者的疗效及对炎性水平的影响。方法54例急性肺挫伤患者,根据用药治疗方法不同分为研究组与对照组,每组27例。研究组给予西维来司他钠治疗,对照组给予多索茶碱治疗。比较两组患者治疗前后动脉血气指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))、动脉血氧饱和度(SaO_(2))]、炎性因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]及不良反应发生情况、生存情况。结果治疗后,两组患者IL-6、TNF-α、CRP水平均低于本组治疗前,且研究组患者IL-6(9.62±3.03)ng/L、TNF-α(37.12±9.02)ng/L、CRP(5.03±1.39)mg/L低于对照组的(13.76±3.21)ng/L、(48.27±11.26)ng/L、(7.74±2.11)mg/L,差异具有统计学意义(P<0.05)。治疗后,两组患者PaO_(2)、SaO_(2)高于本组治疗前,PaCO_(2)低于本组治疗前,且研究组患者PaO_(2)(80.34±8.69)mm Hg(1 mm Hg=0.133 kPa)、SaO_(2)(95.93±6.41)%高于对照组的(64.35±5.48)mm Hg、(86.22±7.45)%,PaCO_(2)(40.57±5.22)mm Hg低于对照组的(51.42±5.54)mm Hg,差异具有统计学意义(P<0.05)。研究组患者治疗总有效率为92.59%,高于对照组的70.37%,差异具有统计学意义(P<0.05)。两组患者均未出现明显的不良反应,用药安全性高。结论西维来司他钠治疗急性肺挫伤患者效果显著,且安全性高,可以有效改善患者动脉血气指标,降低炎性反应,有显著的临床用药价值,值得推广应用。Objective To investigate the efficacy of sivelestat sodium in the treatment of patients with acute pulmonary contusion and influence on inflammatory factors.Methods A total of 54 cases of patients with acute pulmonary contusion were divided into research group and control group according to different treatment methods,with 27 cases in each group.The research group was treated with sivelestat sodium,and the control group was treated with doxofylline.Both groups were compared in terms of arterial blood gas indexes[arterial partial pressure of oxygen(PaO_(2)),arterial partial pressure of carbon dioxide(PaCO_(2)),blood oxygen saturation(SaO_(2))],inflammatory factors[interleukin-6(IL-6),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)]before and after treatment,occurrence of adverse reactions,and survival.Results After treatment,the levels of IL-6,TNF-αand CRP in both groups were lower than those before treatment in this group;the research group had IL-6 of(9.62±3.03)ng/L,TNF-αof(37.12±9.02)ng/L and CRP of(5.03±1.39)mg/L,which were lower than those of(13.76±3.21)ng/L,(48.27±11.26)ng/L and(7.74±2.11)mg/L in the control group;the differences were statistically significant(P<0.05).After treatment,PaO_(2) and SaO_(2) in both groups were higher than those before treatment in this group,while PaCO_(2) was lower than that before treatment in this group;PaO_(2) of(80.34±8.69)mm Hg(1 mm Hg=0.133 kPa)and SaO_(2) of(95.93±6.41)%in the research group were higher than those of(64.35±5.48)mm Hg and(86.22±7.45)%in the control group;PaCO_(2) of(40.57±5.22)mm Hg in the research group was lower than that of(51.42±5.54)mm Hg in the control group;the differences were statistically significant(P<0.05).The total effective rate of the research group was 92.59%,which was higher than that of 70.37%in the control group,and the difference was statistically significant(P<0.05).There were no obvious adverse reactions in both groups,and the drug safety was high.Conclusion Sivelestat sodium is effective and safe in the treatm

关 键 词：急性肺挫伤 西维来司他钠 疗效 炎性因子水平 影响 

分 类 号：R563.8[医药卫生—呼吸系统]